Key result
Exogenous Prostaglandin E2 significantly reduced the expression of fibrogenic and inflammatory genes while inducing brown adipocyte markers (UCP1 and PRDM16) and inhibiting lipolysis in human obese visceral adipose tissue.
Why the study?
Does exogenous addition of Prostaglandin E2 (PGE2) reduce inflammation and fibrosis and improve adaptive thermogenesis in human obese visceral WAT?
Does exogenous addition of Prostaglandin E2 (PGE2) reduce inflammation and fibrosis and improve adaptive thermogenesis in human obese visceral WAT?
PGE2 acts as a key regulator in human obese visceral white adipose tissue, reducing inflammation and fibrosis while promoting adaptive thermogenesis and inhibiting lipolysis.
PGE2 effects on adipocytes are hypothesis-generating; human studies needed before considering therapeutic translation in obesity.
Obesity induces white adipose tissue (WAT) dysfunction characterized by unremitting inflammation and fibrosis, impaired adaptive thermogenesis and increased lipolysis. Prostaglandins (PGs) are powerful lipid mediators that influence the homeostasis of several organs and tissues. The aim of the current study was to explore the regulatory actions of PGs in human omental WAT collected from obese patients undergoing laparoscopic bariatric surgery. In addition to adipocyte hypertrophy, obese WAT showed remarkable inflammation and total and pericellular fibrosis. In this tissue, a unique molecular signature characterized by altered expression of genes involved in inflammation, fibrosis and WAT browning was identified by microarray analysis. Targeted LC-MS/MS lipidomic analysis identified increased PGE2 levels in obese fat in the context of a remarkable COX-2 induction and in the absence of changes in the expression of terminal prostaglandin E synthases (i.e. mPGES-1, mPGES-2 and cPGES). IPA analysis established PGE2 as a common top regulator of the fibrogenic/inflammatory process present in this tissue. Exogenous addition of PGE2 significantly reduced the expression of fibrogenic genes in human WAT explants and significantly down-regulated Col1α1, Col1α2 and αSMA in differentiated 3T3 adipocytes exposed to TGF-β. In addition, PGE2 inhibited the expression of inflammatory genes (i.e. IL-6 and MCP-1) in WAT explants as well as in adipocytes challenged with LPS. PGE2 anti-inflammatory actions were confirmed by microarray analysis of human pre-adipocytes incubated with this prostanoid. Moreover, PGE2 induced expression of brown markers (UCP1 and PRDM16) in WAT and adipocytes, but not in pre-adipocytes, suggesting that PGE2 might induce the trans-differentiation of adipocytes towards beige/brite cells. Finally, PGE2 inhibited isoproterenol-induced adipocyte lipolysis. Taken together, these findings identify PGE2 as a regulator of the complex network of interactions driving uncontrolled inflammation and fibrosis and impaired adaptive thermogenesis and lipolysis in human obese visceral WAT.
No takes yet. Share an insight, caveat, or question.
García‐Alonso et al. (2016) studied Obesity (n=22). Prostaglandin E2 (PGE2) vs. Vehicle was evaluated on Expression of fibrogenic genes, inflammatory genes, brown adipocyte markers, and lipolysis in adipose tissue explants and adipocytes. Exogenous Prostaglandin E2 significantly reduced the expression of fibrogenic and inflammatory genes while inducing brown adipocyte markers (UCP1 and PRDM16) and inhibiting lipolysis in human obese visceral adipose tissue.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: